BAFF is increased in renal transplant patients following treatment with alemtuzumab

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1835-1845

  Bloom, D ^a   Chang, Z ^a   Pauly, K ^a   Kwun, J ^b   Fechner, J ^a   Hayes, C ^c   Samaniego, M ^a   Knechtle, S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alemtuzumab; BAFF; Campath 1H; Renal transplant; Sirolimus

Indexed keywords

ALEMTUZUMAB; APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CD14 ANTIGEN; CD19 ANTIBODY; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; RAPAMYCIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ADULT; AGED; ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-CELL ACTIVATING FACTOR; B-CELL MATURATION ANTIGEN; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; YOUNG ADULT;

EID: 67650938547     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02710.x     Document Type: Article

References (45)

1. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006 81 : 81 87.
2. Noris M, Casiraghi F, Todeschini M et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007 18 : 1007 1018.
3. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76 : 120 129.
4. Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004 78 : 919 924.
5. Knechtle SJ, Pirsch JD, Fechner H et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3 : 722 730.
6. Pascual J, Bloom D, Torrealba J et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008 8 : 1529 1536.
7. Pascual J, Pirsch J, Torrealba J et al. Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction. Am J Transplant 2008 8 : 237.
8. Ruggenenti P, Perico N, Gotti E et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007 84 : 956 964.
9. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 351 : 1701 1702.
10. Matsushita T, Fujimoto M, Hasegawa M et al. Elevated serum APRIL levels in patients with systemic sclerosis: Distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007 34 : 2056 2062.
11. Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: Who's who? Autoimmun Rev 2008 7 : 267 271.
12. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003 21 : 231 264.
13. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006 18 : 263 275.
14. Woodland RT, Schmidt MR, Thompson CB. BLyS and B cell homeostasis. Semin Immunol 2006 18 : 318 326.
15. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: Fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007 19 : 327 336.
16. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005 17 : 282 289.
17. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002 109 : 59 68.
18. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999 190 : 1697 1710.
19. Pers JO, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005 1050 : 34 39.
20. Stohl W, Xu D, Kim KS et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005 52 : 2080 2091.
21. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003 62 : 168 171.
22. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum 2003 48 : 3475 3486.
23. Zhang J, Roschke V, Baker KP et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001 166 : 6 10.
24. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003 198 : 937 945.
25. Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005 201 : 195 200.
26. Schaumann DH, Tuischer J, Ebell W, Manz RA, Lauster R. VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 2007 44 : 1606 1612.
27. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol 2001 167 : 6225 6231.
28. Huard B, Arlettaz L, Ambrose C et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004 16 : 467 475.
29. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002 23 : 113 115.
30. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008 19 : 263 276.
31. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005 25 : 189 201.
32. Watanabe R, Fujimoto M, Yazawa N et al. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007 46 : 53 60.
33. Chu VT, Enghard P, Riemekasten G, Berek C. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007 179 : 5947 5957.
34. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006 81 : 1361 1367.
35. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008 67 : 185 192.
36. Li X, Su K, Ji C et al. Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J Immunol 2008 181 : 1012 1018.
37. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A. Effects of immunosuppressive drugs on purified human B cells: Evidence supporting the use of MMF and rapamycin. Transplantation 2008 86 : 1292 1300.
38. Groom J, Mackay F. B cells flying solo. Immunol Cell Biol 2008 86 : 40 46.
39. Elimelakh M, Dayton V, Park KS et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007 92 : 1029 1036.
40. Emmerich F, Bal G, Barakat A et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007 136 : 309 314.
41. Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004 9 : 409 411.
42. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006 6 (5 Pt 1 1084 1085.
43. Otton SH, Turner DL, Frewin R, Davies SV, Johnson SA. Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999 106 : 261 262.
44. Sellam J, Miceli-Richard C, Gottenberg JE et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007 66 : 790 797.
45. Carter RH, Zhao H, Liu X et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005 52 : 3943 3954.